Human Complement Component 9, C9 ELISA Kit

Human Complement Component 9, C9 ELISA Kit

产品详情

产品评价

靶点详情

产品详情

产品评价

相关产品

靶点详情

Most popular with customers

产品中心

信号通路

技术信息

联系信息

中文名称：

人补体蛋白9(C9)酶联免疫试剂盒
货号：

CSB-E14011h
规格：

96T/48T
价格：

￥3600/￥2500
其他：

CUSABIO Wins 2024 Bioz Rapid Star™ Award in the ELISA category

产品详情
产品评价
相关产品
靶点详情

产品描述：

人补体蛋白9(C9)酶联免疫试剂盒（CSB-E14011h）为双抗夹心法ELISA试剂盒，定量检测血清、血浆、尿液样本中的C9含量。人补体蛋白9(C9)是补体系统中的重要成分，参与膜攻击复合物（MAC）的形成，对病原体和异常细胞具有溶解作用。其研究背景涉及衰老、神经退行性疾病等，机制上与补体激活、炎症反应和细胞凋亡密切相关。试剂盒检测范围为10.97 pg/mL-8000 pg/mL，适用于科研领域中对补体系统功能的基础研究，如炎症反应机制解析、自身免疫性疾病模型中的补体激活评估，或通过体液样本探索C9在感染、肾脏疾病等病理条件下的生物标志物价值本品仅用于科研，不用于临床诊断，产品具体参数及操作步骤详见产品说明书。
别名：

C9; Complement component C9
缩写：

C9
Uniprot No.：

P02748
种属：

Homo sapiens (Human)
样本类型：

serum, plasma, urine
检测范围：

10.97 pg/mL-8000 pg/mL
灵敏度：

10.97 pg/mL
反应时间：

1-5h
样本体积：

50-100ul
检测波长：

450 nm
研究领域：

Immunology
测定原理：

quantitative
测定方法：

Sandwich

精密度：

线性度：

To assess the linearity of the assay, samples were spiked with high concentrations of human C9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
	Sample	Serum(n=4)
1:2000	Average %	96
	Range %	90-104
1:4000	Average %	91
	Range %	87-98
1:8000	Average %	95
	Range %	90-110
1:16000	Average %	96
	Range %	89-100

回收率：

The recovery of human C9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

Sample Type	Average % Recovery	Range
Serum (n=5)	96	92-101
EDTA plasma (n=4)	97	87-106

标准曲线：

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

pg/ml	OD1	OD2	Average	Corrected
8000	2.577	2.514	2.546	2.455
2666.7	1.845	1.864	1.855	1.764
888.9	1.239	1.213	1.226	1.135
296.3	0.851	0.844	0.848	0.757
98.8	0.388	0.399	0.394	0.303
32.9	0.214	0.207	0.211	0.120
10.97	0.139	0.142	0.141	0.050
0	0.089	0.093	0.091

数据处理：

ELISA操作视频及标曲绘制软件下载
货期：

3-5 working days

功能：

Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.
基因功能参考文献：
1. The data supports the assumption that C9 gene expression may stimulate the expression of inflammatory (NLRP3) and angiogenic growth factors (VEGF) in retinal pigment epithelial cells. PMID: 30090015
2. Serum-expressed apolipoprotein B-100 protein, C9 Complement, and gelsolin can be used for differential diagnosis of Barrertts esophagus and adenocarcinoma of esophagus. PMID: 26404905
3. Data indicate that complement C9 binds to the ATPase domain of mortalin. PMID: 24719326
4. Liver biopsy specimens from chronically hepatitis C virus-infected patients exhibited a lower level of C9 mRNA expression than liver biopsy specimens from unrelated disease or healthy control human liver RNA. PMID: 23487461
5. the haploinsufficiency of C9, a terminal complement complex component, engenders reduced intraocular secretion of VEGF and decreased risk for CNV development. PMID: 22190594
6. C9 and fucosylated form could serve as a useful marker for SQLC. PMID: 21840429
7. It was concluded that variations in the complement component 9 gene are unlikely to influence clearance of chronic hepatitis B virus infection and hepatocellular carcinoma occurrence. PMID: 21380615
8. Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. PMID: 21507937
9. These results suggested that the lack of membrane attack complex because of an Arg95Stop mutation of the complement component 9 gene predisposed patients to pathognomonic glomerulonephritis. PMID: 21057849
10. provided evidence for the recognition of membrane-bound C9 on complement-lysed ghosts by an antibody specific for the helix-turn-helix fold. PMID: 20153530
11. Data show that mortalin supports cancer cell resistance to complement-dependent cytotoxicity and suggest consideration of mortalin as a novel target for cancer adjuvant immunotherapy. PMID: 19739077
12. The human complement C9 gene: structural analysis of the 5' gene region and genetic polymorphism studies. PMID: 11881818
13. C9 binding is dependent on the N-terminal modules (thrombospondin type 1 and low-density lipoprotein receptor class A) of C8 alpha together with the C8 alpha membrane attack complex/perforin domain. PMID: 12463754
14. Founder effect was demonstrated for the R95X mutation of the C9 gene in Japanese PMID: 12596049
15. results indicate that the principal binding site for C9 lies within the MACPF domain of C8alpha PMID: 16618117
16. analysis of the CD59-C9 binding interaction PMID: 16844690
显示更多

收起更多
相关疾病：

Complement component 9 deficiency (C9D); Macular degeneration, age-related, 15 (ARMD15)
亚细胞定位：

Secreted. Target cell membrane; Multi-pass membrane protein.
蛋白家族：

Complement C6/C7/C8/C9 family
组织特异性：

Plasma (at protein level).
数据库链接：

HGNC: 1358

OMIM: 120940

KEGG: hsa:735

STRING: 9606.ENSP00000263408

UniGene: Hs.654443

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.